EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
8/21/2022 | 1:00 PM - 2:30 PM | Testing Saliva Samples for Newborn CMV Screening | Governor General II
Testing Saliva Samples for Newborn CMV Screening
Introduction: Congenital Cytomegalovirus (cCMV) is the leading non-genetic cause of sensorineural hearing loss (SNHL) and developmental disabilities. Since majority of children with cCMV are asymptomatic and are not identified at birth, screening in the newborn period will allow the identification of most children with cCMV for targeted monitoring and intervention to improve outcomes. For implementation of a screening program, it is necessary to identify an ideal testing sample and methodology that can be adapted for high throughput screening. This instructional session will focus on testing saliva samples collected in the newborn period for identifying children with cCMV. Objective: To discuss the feasibility of implementing a newborn CMV screening program by testing newborn saliva samples for CMV to identify children with cCMV. Format: The session will include a panel of speakers and an interactive session with the audience. Presentation 1: We will briefly discuss the long-term outcomes of cCMV and the importance of newborn screening and merits of targeted vs universal screening program. Presentation 2: This session will summarize data on the use of saliva PCR to identify newborns with cCMV and compare with other specimens for screening. We will describe our experience with saliva PCR testing for cCMV from the CMV & Hearing Mulitcenter Screening (CHIMES) Study and discuss other published studies supporting the use of saliva PCR. Presentation 3: This presentation will discuss the possibility of false positive results with use of saliva PCR for identifying cCMV infants and emphasize the need for standardization and validation of PCR assays when used for cCMV screening. Presentation 4: This presentation will discuss the challenges and real-world experience of implementing newborn CMV screening programs in a hospital setting and integration into EMR and existing screening programs. Q and A session: This session will conclude with panelists taking questions from the audience.
- Describe the burden of congenital CMV infections and the need for a newborn screening program
- Discuss the evidence for using saliva PCR methodology for identification of newborns with congenital CMV infection
- Discuss methods to implement a newborn CMV screening program
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Shannon A. Ross
(), sross@peds.uab.edu;
Dr. Ross is an Associate Professor in the Division of Infectious Diseases, in the Department of Pediatrics.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Swetha Pinninti
(), spinninti@peds.uab.edu;
a
ASHA DISCLOSURE:
Financial -
Nonfinancial -